US 2003/0125343 A1 · Combinations of receptor tyrosine kinase inhibitor with an a1-acidic glycoprotein binding compound

Abstract

This invention relates to combinations of an abl-, PDGF-Receptor-and/or Kit receptor-tyrosine kinase inhibitor with an organic compound capable of binding to α1-acidic glycoprotein (AGP), as well as to pharmaceutical preparations and/or therapies, in relation to disease states which respond to inhibition of abl-, PDGF-Receptor- and/or Kit-receptor tyrosine kinase. In particular, the invention relates to products or combinations comprising and abl-, PDGF-Receptor- and/or Kit receptor-tyrosine kinase inhibitor with an organic compound capable of binding to AGP, either in fixed combination or for chronologically staggered or simultaneous administration, and the combined used of both classes of compounds, either in fixed combination or for chronologically staggered or simultaneous administration, for the treatment of proliferative diseases, especially tumor diseases, especially those that can be treated by inhibition of abl-, PDGF-Receptor- and/or Kit receptor-tyrosine kinase activity.

Claims11

Dependent claims

A combination preparation comprising (a) at least one abl-, PDGF-R- and/or Kit receptor-tyrosine kinase inhibitor and (b) at least one organic compound capable of binding to α1-acidic glycoprotein (AGP);

or pharmaceutically acceptable salts of any component (a), (b) or (a) and (b) if at least one salt-forming group is present, and a pharmaceutically acceptable carrier.

A product which comprises

(a) at least one abl-, PDGF-R- and/or Kit receptor-tyrosine kinase inhibitor and
(b) at least one organic compound capable of binding to α1-acidic glycoprotein,
wherein any component (a) and/or (b) can also be present in the form of a pharmaceutically acceptable salt, if at least one salt-forming group is present,
in the presence or absence of one or more pharmaceutically acceptable carrier materials, as a combination preparation for simultaneous or chronologically staggered use within a period of time which is small enough for the active compounds both of component (a) and of component (b) to enhance antiproliferative activity of compound (a) against proliferating cells, especially in a patient, for treating a proliferative disease which responds to such a compound.

1 more element

Dependencies are inferred from the claim text.

Combinations of receptor tyrosine kinase inhibitor with an a1-acidic glycoprotein binding compound

Life of this patent

Combinations of receptor tyrosine kinase inhibitor with an a1-acidic glycoprotein binding compound

Life of this patent

Abstract

Claims11